skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

ASCO 2018

ASCO 2018 Annual meeting

Register to receive coverage from the Pharma Intelligence team

Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting.

Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

Watch webinar below

 

 

 

 

Immuno Oncology: What To Watch At ASCO 2018

For some years now, immunotherapy has dominated the American Society of Clinical Oncology (ASCO) annual meeting and this year is no exception as it will be a defining week for PD-1/L1 inhibitors and chimeric antigen receptor T-cell therapies.

Drawing from a meeting preview report by Pharma Intelligence’s Biomedtracker and Datamonitor Healthcare analysts following the abstract drop on May 16, we highlight the studies below as important to watch at the meeting, which will be held June 1-5 in Chicago

ASCO 2017

 

ASCO 2017 - Oncology conference - Pharma Ingelligence



Biomedtracker uniquely allows subscribers to stay on top of key meeting developments, even when attending in person isn’t possible. Our expert staff continually reports on the most salient and crucial aspects of meetings and is available to assist subscribers with their questions. Keep pace with breaking events, upcoming milestones, and their impact on the markets you care about with Biomedtracker.

2017 Informa Pharma Intelligence Post-ASCO Podcast

Thanks for your interest in the 2017 Informa Pharma Intelligence Post-ASCO Podcast, your digital audio wrap-up of the most impactful presentations and posters at the 53nd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2-6 in Chicago, Illinois.

Featuring analysts from Informa’s Biomedtracker, Datamonitor Healthcare, and Citeline, the 2017 Informa Pharma Intelligence Post-ASCO Podcast provides commentary into the major events from ASCO 2017: what delivered, and what failed to live up to the buzz.

This podcast is one of the many ASCO-related materials available to subscribers of Biomedtracker. With Biomedtracker, stay on top of key developments, even when you can’t attend a meeting. Our expert staff continually reports on the most salient, crucial aspects of meetings, like ASCO, and is available to answer any subscriber questions that may arise after reviewing meeting materials. Keep pace with breaking events, upcoming milestones, and their impact on the markets you care about with Biomedtracker.


Click here to listen

 

ASCO 2016

Every year the Informa Pharma Intelligence experts analyze the finding that come out during the ASCO annual conference. This year we are delighted to have Dr. Peter Lee from City of Hope Comprehensive Cancer Center weighing in with our analysts on the key takeaways from this year’s conference, its winners and losers, and examine the implications for the future oncology treatment landscape.

This session is hosted by Mary Jo Laffler our US Head of Commercial Content. She is joined by:

Ally Bruce is a Principal Analyst in Oncology and is part of the Citeline team. She has been an Analyst with the group for over a decade, with experience in Oncology, CNS, and Analytics. Prior to Citeline, she was a healthcare consultant in Cambridge, MA, and spent several years coordinating clinical trials in the Psychopharmacology Unit at Tufts Medical School.

Zachary McLellan is an Analyst with Datamonitor Healthcare specializing in the coverage of breast and gynecological malignancies. Zachary has a M.Sc. In Biotechnology and Entrepreneurship from New York University and worked as a chemist prior to joining Informa.

Robert Jeng is a Senior Scientific Analyst overseeing BioMedTracker’s oncology coverage for the past 5 years. Before joining Informa, Robert was a cell biologist who earned his Ph.D. from Stanford University before working as a postdoctoral researcher at Berkeley and a staff scientist at the Sanford-Burnham Institute specializing in cytoskeletal dynamics.

Peter P. Lee, MD is Chair, Department of Immuno-Oncology and Billy Wilder Endowed Professor in Cancer Immunotherapeutics at City of Hope Comprehensive Cancer Center, CA. He also serves as Co-leader, Cancer Immunotherapeutics Program and Professor, Department of Hematology & Hematopoietic Cell Transplantation at COH.

The focus of his research is on understanding how cancer impacts host immune responses in patients, with the goal of developing novel treatments to restore/enhance immune function in cancer patients. His group aims to dissect the complex interplay between immune/stromal cells and cancer cells within tumors, tumor-draining lymph nodes (TDLNs), and blood using experimental and systems biology approaches. His group has shown that lymphocytes from patients with breast cancer, melanoma, and colorectal cancer develop immune signaling defects that blunt their proliferation and function in vivo. He is also extending these findings in multiple directions, including to other human cancers such as prostate cancer and leukemia.

Dr. Lee has published over 50 articles in journals such as Nature Medicine, Proceedings of the National Academy of Science (PNAS), Public Library of Science (PLoS), Medicine, and received many awards, including elected member of the American Society for Clinical Investigation, Department of Defense Era of Hope Scholar Award for Breast Cancer Research, American Cancer Society Research Scholar, and the Damon Runyon Scholar Award. While a fellow at UCSF, Dr. Lee invented the MucoCept technology.

ASCO 2015 Conference Review

Our NEW white paper allows you to read through the results and implications of these key abstracts, chosen by our expert analysts, allowing you and your business to evolve with the oncology market.
ASCO 2015

Highlights from the ASCO 2014 Conference review include:

Results from early-phase clinical trials of AstraZeneca’s AZD9291

Imbruvica's (Ibrutinib; Pharmacyclics/Janssen Biotech) Phase III RESONATE results

Results from the Phase II ROMULUS trial

 

Post-ASCO-2014

Pharma Intelligence latest insights

  • Biomedtracker

    Clinical Trials Industry Report

    By KNect365 17 Aug 2018

    Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.

    Topic Clinical trials Clinical trial optimization

  • Pharma Consulting

    Changing the future of data

    17 Aug 2018

    With fewer successful drug launches in the market and expiring patents, competitive intelligence and commercial R&D decision makers are hard-pressed to make sound forecasting and planning decisions based on highly reliable data analysis. That’s a big challenge because, even with access to big data from many sources, the tasks associated with collecting, organizing and mapping data sets is time-consuming, costly and labour-intensive. As result, decision making takes longer and innovation suffers.

    Topic Business strategies Company analysis

  • Scrip

    Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT

    By Jessica Merrill 17 Aug 2018

    FDA approved Galafold under accelerated approval, paving the way for the launch of the first oral therapy to treat a subset of patients with the rare condition Fabry disease. Amicus priced Galafold at $315,000 per year.

    Topic FDA

  • Scrip

    Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability

    By Sten Stovall 17 Aug 2018

    Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.

    Topic Research Business strategies

  • Medtech Insight

    QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like

    By Shawn M. Schmitt 17 Aug 2018

    US FDA will face high hurdles as it works to write a new rule that would merge the agency's Quality System Regulation with international quality systems standard ISO 13485. That's according to Kim Trautman, a longtime industry insider who wrote the QSR in the early to mid-1990s. "It’s a clear heavy lift from a regulatory policy perspective" that could take as long as five years to complete, she says. In the meantime, Trautman offers some insight into what device-makers might see in a new hybrid quality systems regulation from FDA. She addresses everything from corrective and preventive action (CAPA) to labeling, and complaint handling to risk management – and more.

    Topic FDA

  • Medtech Insight

    Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm

    By Sue Darcey 17 Aug 2018

    The agency has responded to a draft diagnostics reform bill in Congress with proposed reforms that diverge some ways from the proposed legislation, but stick with the underlying goal of completely remaking how lab tests, including test kits and lab-developed tests, are regulated. The agency has put forward a proposal to establish a pre-certification process for test developers, divide most tests into high- or low-risk categories (but exempt many from pre-market review) and remove the concept of substantial equivalence.

    Topic FDA

  • Rose Sheet

    GC3 Announces Preservative Challenge Winners

    By Ryan Nelson 17 Aug 2018

    Avisco, a biotech startup focused on the antimicrobial properties of the Inula viscosa plant, and IMD Natural Solutions, whose INS Glycolipid mushroom extract purportedly is “up to 80 times more effective than traditional preservatives,” are among winners named Aug. 6 by GC3.

    Topic BioPharmaceutical

  • In Vivo

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    By Lucie Ellis 17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic Drug approval Drug review

  • Biomedtracker

    Biomedtracker 2018 Early Outlook Report

    15 Aug 2018

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topic Drug development landscape

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Report Extract

    15 Aug 2018

    Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter. 

    Topic Drug development landscape

  • Meddevicetracker

    Meddevicetracker Q3 2018 Outlook Report Extract

    14 Aug 2018

    In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology,  and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.

  • Scrip

    Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

    By Mandy Jackson 14 Aug 2018

    Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.

    Topic Business strategies Drug approval

  • Scrip

    A Safe Harbor For Biotechs Ascletis BeiGene Mark Early Wins For HK Exchange

    By Jules Quartly 14 Aug 2018

    The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

    Topic Business strategies Company analysis

  • Pink Sheet

    US FDA’s Breakthrough And RMAT Designations: A Quick Guide

    By Bridget Silverman 14 Aug 2018

    Differences in eligibility and evidentiary criteria between the US FDA's two expedited regulatory programs are reflected in a new guide; metrics to date suggest comparable success rates for designation requests under the two programs. Our infographics aid in understanding the programs.

    Topic FDA

  • In Vivo

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 13 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic Cancer

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: